Temperature controlled high energy adjustable multi-mode emission laser therapy (THEAL) is a
new physiotherapy method recently introduced in the treatment of musculoskeletal disorders. The
first published clinical trials show an excellent clinical response in the treatment oflow back pain
(LBP). In view of various protocol modulation modes, we wanted to verify the effect of a protocol
that provided contextual administration of different wavelengths.
We administered to twenty patients a treatment that consisted of ten sessions of Temperature
controlled High Energy Adjustable multi-mode emission Laser therapy (THEAL) (iLux XP/
Ixyon, Mectronic Medicale, Italy), with the simultaneous delivery of 650nm, 810nm and 1064nm
wavelengths.
The patients have been monitored during different follow-ups(FUs)to check the remission of
pain, using Visual Analog Scale (VAS) for pain, Roland Score for functional recovery with and
OswestryScore for regression of disability. Already at the end of the treatment after 10 days, and at
subsequent FUs time at 1, 2, 4 and 12 months, a significant improvement was noticed for all these
scores.
These clinical results are consistent with the expected biological effects for each wavelengththat
we have administered. The 810nm has a strong affinity for modulating no receptive pain, 650nm
wavelengths have a marked anti-inflammatory effect and 1064nm has a decontracting action on
muscles.
The possibility to use a High Energy Laser with adaptive modulating emission and thermal control
of biological tissue (THEAL) allows an optimized energy delivery with good local compliance. The
concomitant administration of these wavelengths would therefore enable action on the various
pathogenic noxa: radicular pain, local inflammation and reactive muscle response